Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548511 | 0.81 | ALDH1A1 (0.75) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL10501732 | 0.81 | KDM4E (0.78) | ALDH1A1TDP1KDM4EHSD17B10KMT2A | |
| SCHEMBL9132832 | 0.80 | HSD17B10 (0.69) | ALDH1A1KDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL791289 | 0.80 | MEN1 (0.71) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL31030743 | 0.80 | ALDH1A1 (0.77) | ALDH1A1KDM4EKMT2AMEN1HPGD | |
| SCHEMBL14085807 | 0.80 | KDM4E (0.76) | ALDH1A1TDP1KDM4EHSD17B10KMT2A | |
| SCHEMBL11306184 | 0.79 | ALDH1A1 (0.65) | ALDH1A1TDP1KDM4EHSD17B10KMT2A | |
| SCHEMBL11575355 | 0.77 | KDM4E (0.72) | ALDH1A1TDP1KDM4EHSD17B10KMT2A | |
| SCHEMBL6699060 | 0.77 | KDM4E (0.72) | ALDH1A1TDP1KDM4EHSD17B10KMT2A | |
| SCHEMBL6695018 | 0.77 | KDM4E (0.72) | ALDH1A1TDP1KDM4EHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56075432-A | — | — | None | — | — | JP | disclosed |
| JP-56075431-A | — | — | None | — | — | JP | disclosed |
| JP-56075430-A | — | — | None | — | — | JP | disclosed |
| EP-4692178-A1 | CELLULOSE POWDER AND MOLDED BODY | Asahi Kasei Kabushiki Kaisha (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12427113-B2 | Cellulose composition, tablet, and orally disintegrating tablet | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-09-30 | — | — | US | disclosed |
| WO-2025121315-A1 | CELLULOSE POWDER AND MOLDED BODY | 旭化成株式会社 | 2025-06-12 | — | — | WO | disclosed |
| US-12290602-B2 | Cellulose powder, use thereof, and tablets | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-05-06 | — | — | US | disclosed |
| EP-4056637-B1 | CELLULOSE COMPOSITION AND TABLET | ASAHI CHEMICAL IND (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024204699-A1 | CELLULOSE POWDER AND MOLDED BODY | 旭化成株式会社 | 2024-10-03 | — | — | WO | disclosed |
| CN-112585192-B | Cellulose powder, use thereof and tablets | 旭化成株式会社 | 2023-11-21 | — | — | CN | disclosed |
| US-20070190017-A1 | Porous cellulose aggregate and formed product composition comprising the same | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1712583-A1 | POROUS CELLULOSE AGGREGATE AND FORMED PRODUCT COMPOSITION COMPRISING THE SAME | Asahi Kasei Chemicals Corporation (JP) | 2006-10-18 | — | — | EP | disclosed |
| EP-1033129-B1 | ANTIMICROBIALS FOR TREATING PEPTIC ULCER | EISAI CO LTD (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-6740667-B2 | Antimicrobial agent | EISAI CO., LTD. (JP) | 2004-05-25 | — | — | US | disclosed |
| US-20030069279-A1 | Antimicrobial agent | EISAI CO., LTD. | 2003-04-10 | — | — | US | disclosed |
| US-6426369-B1 | MIXTURE WITH PROTON PUMP INHIBITOR | EISAI CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1033129-A1 | ANTIMICROBIALS | Eisai Co., Ltd. (JP) | 2000-09-06 | — | — | EP | disclosed |
| JP-S5675432-A | ANTITUMOR AGENT CONTAINING ETHYL PIPERIDYLACETYLAMINOBENZOATE | TAKABE AYANORI | 1981-06-22 | — | — | JP | disclosed |
| JP-S5675431-A | HYPOGLYCEMIC AGENT CONTAINING ETHYL PIPERIDYLACETYLAMINOBENZOATE | TAKABE AYANORI | 1981-06-22 | — | — | JP | disclosed |
| JP-S5675430-A | ANTIARTERIOSCLEROTIC AGENT CONTAINING ETHYL PIPERIDYLACETYLAMINOBENZOATE | TAKABE AYANORI | 1981-06-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069279-A1 | Antimicrobial agent | HRH2, PGC, GRPR | ALDH1A1 246/4885TDP1 4297/4885KDM4E 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.